Vancouver, British Columbia – TheNewswire – October 19, 2020 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (the “Corporation” or “Blackhawk“), is pleased to provide the following corporate update.
The Health Canada Interim Order (“IO”) application was completed and submitted for the ExProbe SARS-CoV-2 Testing Kit. The Company received confirmation of receipt from Health Canada on October 14, 2020. Even though Blackhawk cannot guarantee timelines, the anticipated time to process the application is between 40 and 60 days.
The IO process for the SARS-CoV-2 IgG/IgM Rapid Test Kit is scheduled to be submitted as soon as it is completed. The application process, though similar, has many more parameters and thus requires more time to prepare. Health Canada timelines will vary on a case by case basis for an IO application review. As we understand, currently this duration is closer to 4 weeks from the time of submission but could take longer depending on the extent of information requests received from Health Canada.
Blackhawk makes no representations or provide any guarantees on Health Canada review timelines, or that any particular application will be successful.
We would also like to confirm that Blackhawk has obtained its Medical Device Establishment License (MDEL) and will be acting as the agent for the manufacturer in Canada. The ExProbe SARS-CoV-2 Testing Kit was submitted with Blackhawk as the agent.
NuWave is expecting to receive the finalized contract for its larger-scale equipment this week as negotiations have completed. NuWave has added multiple baked goods to its exclusivity to be produced in its Edmonton facility. NuWave has also added exclusivity for the drying of psilocybin mushrooms internationally where regulations or licencing allow. The Company will provide further updates when they become available.
Trip Pharma has secured the location for its first Canadian clinic. The clinic will be Situated on a prominent corner of the warehouse district in Edmonton’s historic MacCosham building. Modifications and outfitting are currently underway. Trip Pharma plans to keep the character of the original architectural features including the heavy wooden beams and columns, brick walls, hardwood floors and heavy timber ceilings. Utilizing just under 5,000 Sq feet on the main and second floors, the clinic is spacious enough for exam rooms built for the post-pandemic era. Initial staff has been secured and Dr. Krista Leicht intends to move her current practice to this facility as soon as upgrades have been completed. At capacity, the clinic will be able to support 11 medical professionals. The intended occupants of this clinic will be Psychiatrists, Psychologists, and General Practitioners. Blackhawk’s “Talk to Doc” platform will be the official telemedicine platform for the Trip Pharma clinic.
Picture of the clinic below – more pictures will be available upon completion of the upgrades.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws, including with respect to completion and review by Health Canada of interim order applications, and completion of a large-scale equipment contract by NuWave. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation’s public filings under the Corporation’s SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.